Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy

PartnershipZegfrovyPositive

AI Analysis

Summary

Dizal has granted AstraZeneca worldwide exclusive rights to develop and commercialize Zegfrovy under a licensing agreement. Dizal will receive an upfront payment of $600M, milestone payments up to $900M, and tiered royalties on global sales.

Outcome Details

Global exclusive license agreement for development and commercialization

Importance:7/10

Sentiment:

0.70

licensingpartnershipexclusive agreementmilestone paymentsroyalties

Related Companies

$AZN

Read the original article

Published by PR Newswire Pharma on July 14, 2026 6:00 AM

Read Original